诺诚健华于近日发布2026年中期业绩。期内，公司实现营收约11.37亿元，同比上涨55.5%。经调整净利润约2.77亿元，而上年同期为亏损约0.16亿元，实现同比扭亏为盈。公司表示，营收增长主要受多元化产品组合持续拓展及已有产品市场渗透率提升推动。
从成本结构看，销售及分销开支约2.69亿元，同比上涨10.3%；研发开支约4.97亿元，同比上涨10.5%；行政开支约1.12亿元，同比提升18.4%。期内毛利率约89.5%，与去年同期水平基本持平。上半年经营活动净现金流为0.81亿元。
业务方面，药物销售取得强劲增长。公司上半年相关收入约9.18亿元，同比上升43.2%，在奥布替尼等核心产品带动下，毛利亦同步增长。其余领域中，自身免疫性疾病与实体瘤管线继续取得多项临床与监管进展。
上述财报并未披露下个财报期的具体业绩指引。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.